Condition

Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials and research

• 7Clinical trials
• 1Country

Newest Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials

All recruiting trials (7)

• Sintilimab plus anlotinib and a taxane for recurrent or metastatic nasopharyngeal carcinoma

  This trial will test whether adding the PD‑1 drug sintilimab and the oral anti‑angiogenic anlotinib to a taxane chemotherapy helps adults with recurrent or metastatic nasopharyngeal carcinoma who have already failed platinum chemotherapy and/or prior anti‑PD‑1/PD‑L1 therapy.

  Recruiting Phase 2 Sun Yat-sen University · Zhuhai, Guangdong · NCT07581821

• YL201 with toripalimab, with or without cisplatin, for recurrent or metastatic nasopharyngeal carcinoma

  This trial tests whether adding the experimental drug YL201 to toripalimab, with or without cisplatin, can help people with recurrent or metastatic nasopharyngeal carcinoma.

  Recruiting Phase 1/2 MediLink Therapeutics (Suzhou) Co., Ltd. · Chongqing, Chongqing Municipality and 19 other locations · NCT07258979

• Combination therapies for PD-1–resistant recurrent or metastatic nasopharyngeal cancer

  This trial will try four different treatment regimens in people with recurrent or metastatic nasopharyngeal cancer who no longer respond to anti‑PD‑1 therapy after prior platinum chemotherapy.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT07070479

• MRG003 plus pucotenlimab versus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma

  This trial tests whether combining MRG003 with pucotenlimab works better than standard chemotherapy for people with recurrent or metastatic nasopharyngeal carcinoma who have had at least one prior systemic treatment.

  Recruiting Phase 3 Lepu Biopharma Co., Ltd. · Guangzhou, Guangdong · NCT06976190

• Combining Irinotecan Liposome with S-1 for advanced Nasopharyngeal Carcinoma

  This study is testing whether a new combination of two medications can help people with advanced nasopharyngeal cancer who haven't responded to previous treatments.

  Recruiting Phase 2 Sun Yat-sen University · Zhuhai, Guangzhou · NCT06657690

• Combining Mitoxantrone Hydrochloride Liposome with PD-1 Blockade for Advanced Nasopharyngeal Carcinoma

  This study is testing a new treatment that combines a special chemotherapy drug with a PD-1 blocker to see if it helps people with advanced nasopharyngeal cancer who haven't responded to previous treatments.

  Recruiting Phase 2 Sun Yat-sen University · Zhuhai, Guangdong · NCT06472713

• Combining AK104 with chemotherapy for advanced nasopharyngeal carcinoma

  This study is testing if a new treatment called AK104, when combined with chemotherapy, can help people with advanced nasopharyngeal cancer who haven't had success with earlier treatments.

  Recruiting Phase 2/3 Sun Yat-sen University · Guangzhou, Guangdong · NCT06241599

Related topics

Quick answers

How many Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 3: 1, Phase 2/3: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →